ReviewTranslational stroke research2013
Steps to translate preconditioning from basic research to the clinic.
Review in Translational stroke research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cerebral Ischemic Preconditioning Aggravates Death of Oligodendrocytes.Biomolecules · 2022Article
- The neuroprotective effect of pretreatment with carbon dots from Crinis Carbonisatus (carbonized human hair) against cerebral ischemia reperfusion injury.Journal of nanobiotechnology · 2021Article
- Review Cerebral Ischemic Tolerance and Preconditioning: Methods, Mechanisms, Clinical Applications, and Challenges.Frontiers in neurology · 2020Review
- Electroacupuncture Pretreatment Elicits Tolerance to Cerebral Ischemia/Reperfusion through Inhibition of the GluN2B/m-Calpain/p38 MAPK Proapoptotic Pathway.Neural plasticity · 2020Article
- Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up.Translational stroke research · 2017Article
- Hyperbaric oxygen preconditioning: a reliable option for neuroprotection.Medical gas research · 2016Review
- Translational intracerebral hemorrhage: a need for transparent descriptions of fresh tissue sampling and preclinical model quality.Translational stroke research · 2015Article
- Ischemic conditioning-induced endogenous brain protection: Applications pre-, per- or post-stroke.Experimental neurology · 2015Review
- A cost-effective rabbit embolic stroke bioassay: insight into the development of acute ischemic stroke therapy.Translational stroke research · 2015Article
- Cannabinoid receptor type 2 agonist attenuates apoptosis by activation of phosphorylated CREB-Bcl-2 pathway after subarachnoid hemorrhage in rats.Experimental neurology · 2014Article
- Full steam ahead with remote ischemic conditioning for stroke.Translational stroke research · 2014Article
- Vascular neural network in subarachnoid hemorrhage.Translational stroke research · 2014Article
- Effects of catalpol on ATPase and amino acids in gerbils with cerebral ischemia/reperfusion injury.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2014Article
- Small molecule inhibitors in the treatment of cerebral ischemia.Expert opinion on pharmacotherapy · 2014Review
- Vascular neural network: the importance of vein drainage in stroke.Translational stroke research · 2014Article
- Fast neuroprotection (fast-NPRX) for acute ischemic stroke victims: the time for treatment is now.Translational stroke research · 2013Article
- Acute bioenergetic intervention or pharmacological preconditioning protects neuron against ischemic injury.Journal of experimental stroke & translational medicine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Efforts to treat cardiovascular and cerebrovascular diseases often focus on the mitigation of ischemia-reperfusion (I/R) injury. Many treatments or "preconditioners" are known to provide substantial protection against the I/R injury when administered prior to the event. Brief periods of ischemia itself have been validated as a means to achieve neuroprotection in many experimental disease settings, in multiple organ systems, and in multiple species suggesting a common pathway leading to tolerance. In addition, pharmacological agents that act as potent preconditioners have been described. Experimental induction of neuroprotection using these various preconditioning paradigms has provided a unique window into the brain's endogenous protective mechanisms. Moreover, preconditioning agents themselves hold significant promise as clinical-stage therapies for prevention of I/R injury. The aim of this article is to explore several key steps involved in the preclinical validation of preconditioning agents prior to the conduct of clinical studies in humans. Drug development is difficult, expensive and relies on multi-factorial analysis of data from diverse disciplines. Importantly, there is no single path for the preclinical development of a novel therapeutic and no proven strategy to ensure success in clinical translation. Rather, the conduct of a diverse array of robust preclinical studies reduces the risk of clinical failure by varying degrees depending upon the relevance of preclinical models and drug pharmacology to humans. A strong sense of urgency and high tolerance of failure are often required to achieve success in the development of novel treatment paradigms for complex human conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.